Asia Pacific Insomnia Market

Asia Pacific Insomnia Market Size, Share & Industry Trends Analysis Report By Distribution Channel (Hospital, Retail, and Others), By Therapy Type (Pharmacological and Non-Pharmacological), By Country and Growth Forecast, 2022 - 2028

Report Id: KBV-11397 Publication Date: September-2022 Number of Pages: 71
Special Offering:
Industry Insights | Market Trends
Highest number of Tables | 24/7 Analyst Support

Market Report Description

The Asia Pacific Insomnia Market would witness market growth of 4.9% CAGR during the forecast period (2022-2028).

The introduction of technologically advanced medical devices, the rise in the geriatric population, the availability of patented molecules on the market, potential drugs in the clinical pipeline, and potential drugs all have an impact on the growth of the insomnia therapeutics market. Also, nowadays people are becoming more aware of the ill effects of sleep deprivation and thus are well aware of insomnia and its effect.

An irregular bedtime schedule, stimulating activities right before bed, an uncomfortable sleeping environment, as well as using the bed for work, eating, or watching TV are all examples of poor sleep habits. The sleep cycle can be disrupted by using smartphones, TVs, computers, video games, or other screens right before bed which may lead to insomnia. A small snack before bed is acceptable, but if someone eats too much, they might feel physically uncomfortable when lying down. Heartburn, or the backflow of acid & food into the esophagus after eating, is another common condition that can keep people awake.

After the COVID-19 pandemic, "regular" people were exposed to "exceptional events," which led to mental health issues. There are numerous presentations, including emotional issues such as anxiety & sadness, physiologic effects like sleep disruptions and hunger, severe mental illness, and substance abuse. A small percentage of people with these symptoms may encounter serious mental health issues that necessitate additional mental health care, but the majority only experience mild, transient symptoms.

This group may include young children, pregnant women, the elderly, people who already have a mental illness, people who live alone. Another critical element is how the pandemic has affected first aid workers psychologically. The pandemic & widespread social and economic destruction have had a mental toll on society that is unprecedented in modern times, and this is what is fueling the expansion of the insomnia market in this region.

The China market dominated the Asia Pacific Insomnia Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $428.3 million by 2028. The Japan market is anticipated to grow at a CAGR of 4.3% during (2022 - 2028). Additionally, The India market would experience a CAGR of 5.5% during (2022 - 2028).

Based on Distribution Channel, the market is segmented into Hospital, Retail, and Others. Based on Therapy Type, the market is segmented into Pharmacological and Non-Pharmacological.Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

Free Valuable Insights: The Worldwide Insomnia Market is Projected to reach USD 5.7 Billion by 2028, at a CAGR of 3.9%

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Currax Pharmaceuticals LLC (Currax Holdings USA LLC), Eisai Co., Ltd., Merck Group, Pfizer, Inc., Vanda Pharmaceuticals, Inc., Cadila Healthcare Ltd. (Zydus Cadila), Sanofi S.A., Viatris, Inc., Takeda Pharmaceutical Company Limited, and Purdue Pharma L.P.

Scope of the Study

Market Segments Covered in the Report:

By Distribution Channel

  • Hospital
  • Retail
  • Others

By Therapy Type

  • Pharmacological
  • Non-Pharmacological

By Country

  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific

Key Market Players

List of Companies Profiled in the Report:

  • Currax Pharmaceuticals LLC (Currax Holdings USA LLC)
  • Eisai Co., Ltd.
  • Merck Group
  • Pfizer, Inc.
  • Vanda Pharmaceuticals, Inc.
  • Cadila Healthcare Ltd. (Zydus Cadila)
  • Sanofi S.A.
  • Viatris, Inc.
  • Takeda Pharmaceutical Company Limited
  • Purdue Pharma L.P.
Need a report that reflects how COVID-19 has impacted this market and its growth? Download Free Sample Now


Call: +1(646) 600-5072


  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities

Unique Offerings Unique Offerings

  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Support with 10% customization free after sale

Trusted by over
5000+ clients

Our team of dedicated experts can provide you with attractive expansion opportunities for your business.

Client Logo